Patents Examined by Ronald Schwadron
-
Patent number: 9896505Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.Type: GrantFiled: October 8, 2014Date of Patent: February 20, 2018Assignee: MedImmune, LLCInventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
-
Patent number: 9708380Abstract: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.Type: GrantFiled: April 28, 2011Date of Patent: July 18, 2017Assignee: LEUKOLECT ASInventors: Bernt Th. Walther, Mirushe Miftari
-
Patent number: 9701965Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful for production of proteins.Type: GrantFiled: November 7, 2014Date of Patent: July 11, 2017Assignee: MODERNATX, INC.Inventors: Jason P. Schrum, Gregory J. Sieczkiewicz, Kenechi Ejebe, Sayda M. Elbashir
-
Patent number: 9616120Abstract: The invention provides antibody to canine or feline or equine antigens. Specifically, antibodies directed to canine CD20 which have been caninized or felinized are provided. Also provided are methods for preparing high affinity antibodies to canine and feline CD20 as well as methods for treating B cell disorders in companion animals.Type: GrantFiled: March 15, 2011Date of Patent: April 11, 2017Assignee: VET THERAPEUTICS, INC.Inventor: Genevieve Hansen
-
Patent number: 9546371Abstract: The present invention concerns a chimeric polypeptide comprising several polypeptide domains, which is capable of being secreted in association with membrane vesicles and in particular exosomes. The present invention also concerns a polypeptide constituted by one of said domains for the secretion of a peptide or polypeptide of interest in association with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and of polynucleotides coding for said polypeptides for the production of immunogenic compositions based on exosomes or based on DNA or for screening protein interactions.Type: GrantFiled: March 18, 2009Date of Patent: January 17, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCE ET TECHNIQUESInventors: Robert Zaine El Abiddine Mamoun, Bernadette Nadine Trentin, Michel Vidal
-
Patent number: 9371514Abstract: The present invention is directed to isolated populations of human natural immunoglobulin-producing B1 lymphocytes, wherein the B1 lymphocytes display surface biomarkers CD20, CD43 and CD27 and are either CD11b+ or GD11b?. The present invention is also directed to a method of isolating human natural immunoglobulin-producing B1 lymphocytes from a blood sample comprising isolating B lymphocytes from the sample that express surface biomarkers CD20, CD43 and CD27, and, optionally, CD11b. In addition, the present invention is directed to a methods for diagnosing a B1 cell disorder in a patient, determining the prognosis of a patient having a B1 cell disorder, and treating a patient having a B1 cell disorder.Type: GrantFiled: September 22, 2011Date of Patent: June 21, 2016Assignee: The Feinstein Institute for Medical ResearchInventors: Thomas L. Rothstein, Daniel O. Griffin, Nichol E. Holodick
-
Patent number: 9340577Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. One such peptide, NMLSTVLGV (SEQ ID NO: 183) is useful to elicit an immune response against influenza. The present invention also provides a heteropolymer of an isolated immunogenic peptide less than 15 amino acids in length comprising the oligopeptide NMLSTVLGV (SEQ ID NO: 183) and at least one different peptide.Type: GrantFiled: April 6, 2004Date of Patent: May 17, 2016Assignee: Epimmune Inc.Inventors: Howard M. Grey, Alessandro Sette, John Sidney, Scott Southwood, Ralph T. Kubo, Esteban Celis, Robert Chesnut, W. Martin Kast
-
Patent number: 9228008Abstract: The invention provides canine CD20 specific antibodies, methods of making the antibodies and methods of use of the antibodies.Type: GrantFiled: November 8, 2010Date of Patent: January 5, 2016Assignee: IDEXX Laboratories, Inc.Inventor: Melissa J. Beall
-
Patent number: 9101609Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.Type: GrantFiled: April 13, 2009Date of Patent: August 11, 2015Assignee: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: Philip Tan, Sandy A Simon, Charles G Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A Ledbetter, Martha S Hayden-Ledbetter, Peter A Thompson, Cecile Morales
-
Patent number: 9102722Abstract: Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.Type: GrantFiled: September 23, 2013Date of Patent: August 11, 2015Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
-
Patent number: 9045543Abstract: The present invention discloses a humanized anti-CD20 antibody, which comprises a heavy chain comprising a polypeptide according to one of SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 36; and a light chain comprising apolypeptide according to one of SEQ ID NO: 34, SEQ ID NO: 35, or SEQ ID NO: 37. Comparing to murine-derived antibodies and human-mouse chimeric antibodies, said humanized anti-CD20 antibody maintains or improves high binding activity of the variable regions, meanwhile reduces the immunogenicity of chimeric antibodies, consequently achieves the effect of reducing medicine side effects and improving clinical treatment. The antibody disclosed by the present invention is efficiently expressed in animal cells, can be used for industrial production. It could be used in treating B cell lymphoma, leukaemia, or B cell-associated autoimmune disease with a wide application prospect.Type: GrantFiled: March 16, 2011Date of Patent: June 2, 2015Assignee: Bioex Therapeutics, Inc.Inventors: Jie Liu, Yongke Zhang
-
Patent number: 8900600Abstract: The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).Type: GrantFiled: April 2, 2009Date of Patent: December 2, 2014Assignee: VAXON BiotechInventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
-
Patent number: 8883992Abstract: Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.Type: GrantFiled: October 26, 2012Date of Patent: November 11, 2014Assignee: Medimmune, LLCInventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
-
Patent number: 8859278Abstract: Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human monoclonal antibodies. Human Karyochi cells are made by isolating a donor nucleus that is substantially free of cytoplasm from either a first malignant B-lymphocyte cell line or a normal B-lymphocyte, and transferring the donor nucleus into the cytoplasm of a recipient cell from a second T- or B-lymphoid cell line. With time the nuclei synchronize and fuse to form the chimeric Karyochi fusion partner cell line. Nuclear transfer can be accomplished using intra-cytosolic nucleus injection or by impact-induced nucleus administration.Type: GrantFiled: August 25, 2006Date of Patent: October 14, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Ilya Trakht, Gavreel Kalantarov
-
Patent number: 8815242Abstract: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian. The antibody molecules have a heavy chain and a light chain whose amino acid sequences set forth in SEQ ID NOs: 4 and 5 and exhibit an increased level of cytotoxicity as compared to anti-CD20 antibody molecules produced in CHO cells.Type: GrantFiled: May 27, 2010Date of Patent: August 26, 2014Assignee: Synageva BioPharma Corp.Inventor: Alex J. Harvey
-
Patent number: 8545843Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.Type: GrantFiled: September 20, 2010Date of Patent: October 1, 2013Assignees: Genentech, Inc., Biogen Idec Inc.Inventors: John G. Curd, Antonio J. Grillo-Lopez
-
Patent number: 8545850Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.Type: GrantFiled: November 5, 2010Date of Patent: October 1, 2013Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Patent number: 8475793Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: GrantFiled: February 6, 2009Date of Patent: July 2, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Rene De Waal Malefyt, Leonard G. Presta
-
Patent number: 8465741Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.Type: GrantFiled: September 14, 2007Date of Patent: June 18, 2013Assignee: MMRGlobal, Inc.Inventors: Gerhard Frey, Bruce E. Kimmel, Abraham Anderson